# ResQ-209 (NCT06710288)

> A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

No report yet. It can be ordered.

- Drugs tested: M-CENK plus nogapendekin alfa inbakicept (N-803) plus gemcitabine
- Indication: recurrent platinum-resistant high-grade ovarian cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06710288
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: ImmunityBio, Inc.
- Conditions: Platinum-resistant Ovarian Cancer
- Interventions: Gemcitabine; N-803; M-CENK
- Enrollment: 20
- Primary outcome: Evaluate Progression Free Survival (PFS)
- Primary outcome: Evaluate Overall Survival (OS)
- Primary outcome: Evaluate Objective Response Rate (ORR)
- Primary outcome: Evaluate Duration of Response (DOR)
- Primary outcome: Evaluate Disease Control Rate (DCR)
- Primary outcome: Evaluate the time to progression or death on the next line of treatment (PFS2) of participants receiving M-CENK adoptive cell therapy and N-803 in combination with gemcitabine.
- Primary outcome: Evaluate the CA-125 response rate (RR) per Gynecologic Cancer Intergroup (GCIC) CA-125 criteria.

## Indexed commentary on ResQ-209 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=resq-209-nct06710288
